CD4 and neoplasm: reported that the immune-related indices (CD4+/CD8+) and incidence of adverse reactions in the combination group were greater than those in the single treatment group and that KLX combined with DC-CIK could significantly improve the immune function of patients with advanced gastric cancer, alleviate clinical symptoms, mitigate the toxic side effects of chemotherapeutic drugs, and delay tumor progression (136).